Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial
Titel:
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial
Auteur:
Fleishaker, Dona L Garcia Meijide, Juan A Petrov, Andriy Kohen, Michael David Wang, Xin Menon, Sujatha Stock, Thomas C Mebus, Charles A Goodrich, James M Mayer, Howard B Zeiher, Bernhardt G